Aralen
Formulated to treat malaria to mitigate parasitic infection in the blood.
Strengths: 250 · 500mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Avloclor; Nivaquine
- Therapeutic class
Antimalarial
- Pharmacological class
Aminoquinoline
- Known off-label uses
rheumatoid arthritis; systemic lupus erythematosus
- Contraindications
retinal damage; hypersensitivity; pre-existing visual field changes
- Minor side effects
nausea; headache; diarrhoea
- Moderate side effects
skin pigmentation; rash; visual disturbance
- Dosage forms
Tablet
- Administration route
Oral use
- Patient summary
Formulated to treat malaria to mitigate parasitic infection in the blood.
- Prescription status
POM
- Manufacturer
Sanofi
- Onset Time
1–2 hours
- Duration
varies by treatment length
- Storage instructions
Store below 25°C.
- Drug interactions
Ciclosporin; Tamoxifen
- Age restrictions
Safe for use in children if dosed by weight.
Precautions and warnings
routine eye examinations required; use with caution in psoriasis; may cause cardiac conduction issues
Serious side effects
retinopathy — requires immediate medical attention; qt interval prolongation — requires immediate medical attention
Mechanism of action
This medication functions by interfering with the growth of parasites in the red blood cells, effectively eradicating the malaria-causing organisms.
Pregnancy and breastfeeding
Pregnancy: Use is acceptable for malaria treatment where benefit outweighs risk. Breastfeeding: Safe in recommended doses.
Aralen
Formulated to treat malaria to mitigate parasitic infection in the blood.
Editorial Notes
- Active ingredient(s): Chloroquine
- Listed indication(s): Malaria
Usually available as
- 180 tablets - 250 mg268-250-mg-2038
- 90 tablets - 500 mg268-500-mg-2042